| Outcome Measures: |
Primary: Safety analyses after single dose of ATR-258, Safety analyses will be performed based in incidence of TEAEs after single dose of ATR-258, maximum 7 days post dosing|Safety analyses after multiple doses of ATR-258, Safety analyses will be performed based in incidence of TEAEs after multiple doses of ATR-258, maximum 56 days post dosing | Secondary: PK analyses will be performed after PK of ATR-258 single dose, PK analyses will be performed based on AUC0-inf of ATR-258 in plasma, maximum 7 days post dosing|PK analyses will be performed after PK of ATR-258 single dose, PK analyses will be performed based on AUC0-tz of ATR-258 in plasma, maximum 7 days post dosing|PK analyses will be performed after PK of ATR-258 single dose, PK analyses will be performed based on Cmax of ATR-258 in plasma, maximum 7 days post dosing|PK analyses will be performed after PK of ATR-258 multiple dose, PK analyses will be performed based on AUCtau of ATR-258 in plasma, maximum 56 days post dosing|PK analyses will be performed after PK of ATR-258 multiple dose, PK analyses will be performed based on AUC0-tz,MD of ATR-258 in plasma, maximum 56 days post dosing|PK analyses will be performed after PK of ATR-258 multiple dose, PK analyses will be performed based on Cmax,MD of ATR-258 in plasma, maximum 56 days post dosing
|
